{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-076575","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.093114+00:00","generated_at":"2026-05-16T00:00:53.640854+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"OPKO Health Q4 revenue $148.5M, net loss $31.3M; Regeneron deal >$1B","bullets":["Q4 revenue $148.5M (down 19% YoY); net loss $31.3M ($0.04/share) vs $14.0M income in Q4 2024.","Regeneron collaboration for multispecific antibodies: upfront + milestones >$200M per program, total >$1B.","Pharmaceuticals revenue $43.7M (+17% YoY); NGENLA profit share $12.5M, Rayaldee $8.8M.","Diagnostics revenue $71.1M (down 31% YoY) on asset sale; operating loss improved to $18.3M from $21.7M.","FY 2026 guidance: total revenue $530-560M; total costs $725-750M; R&D $125-135M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-076575","json":"https://secwatch.observer/filing/0001193125-26-076575.json","markdown":"https://secwatch.observer/filing/0001193125-26-076575.md","text":"https://secwatch.observer/filing/0001193125-26-076575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000119312526076575/0001193125-26-076575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000119312526076575/opk-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:00:53.640854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}